Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Dec 5, 2019

Aducanumab is good; next generation Alzheimer’s disease therapies will be better

Nov 18, 2019

ProMIS Neurosciences Completes First Closing of Private Placement

Nov 14, 2019

ProMIS Neurosciences Announces Third Quarter 2019 Results

Nov 13, 2019

ProMIS Neurosciences Undertaking $6.5M Private Placement

Nov 7, 2019

ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease

Nov 7, 2019

ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease

Oct 24, 2019

ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease

Oct 23, 2019

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

Oct 17, 2019

ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau

Oct 17, 2019

ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau

  • arrow_back
  • 1…
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy